J&J's ketamine-based nasal spray Spravato approved by US FDA to treat depression
The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...
FDA approves standalone use of J&J's ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...
Marco Rubio sworn in as U.S. Secretary of State
Rubio wasted no time getting to work. He held a series of meetings at the State Department Tuesday afternoon with foreign ...
Global Pain Management Market To Surge From USD 73.24 Billion In 2023 To USD 108.48 Billion ...
Pain Management Market Advancements in non-opioid therapies, AI-integrated solutions, and regenerative <a target=_blank href= ...
Hydreight and Victory Square Launch $10 Million Health Accelerator to Fuel Nationwide ...
VANCOUVER, British Columbia and LAS VEGAS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing mobile clinical network and ...